Efficacy and safety of semaglutide 1.0 mg once-weekly versus liraglutide 1.2 mg once-daily as add-on to 1-3 oral anti-diabetic drugs (OADs) in subjects with type 2 diabetes
Phase of Trial: Phase III
Latest Information Update: 10 Feb 2019
At a glance
- Drugs Semaglutide (Primary) ; Liraglutide
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SUSTAIN 10
- Sponsors Novo Nordisk
- 31 Aug 2018 Biomarkers information updated
- 16 Aug 2018 Status changed from active, no longer recruiting to completed.
- 14 Dec 2017 Status changed from recruiting to active, no longer recruiting.